Phase 3 Heart Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 85 years old at the time of signing the consent form
• People who have had chronic heart failure with reduced pumping function and have been receiving treatment for it for at least 3 months before the screening visit
• People who are regularly taking water pills (loop diuretics) by mouth
• People without a specific irregular heart rhythm called atrial fibrillation/flutter (AFF) on their heart tracing (ECG) who have a heart pumping function below 30% (measured within the last 6 months) and elevated levels of a heart stress marker in their blood (NT-proBNP ≥ 1000 pg/mL or BNP ≥ 300 pg/mL)
• People with AFF on their ECG who have a heart pumping function below 25% (measured within the last 6 months), elevated heart stress markers in their blood (NT-proBNP ≥ 3000 pg/mL or BNP ≥ 900 pg/mL), and who are not currently taking a medication called digoxin
• People who are currently in hospital primarily because of heart failure, OR who had a significant heart failure event in the past 12 months, OR who had their water pill dose increased or a new water pill type added due to worsening heart failure symptoms lasting at least one week
• People who have been on the standard recommended heart failure treatments for their region for at least 30 days before screening
• People whose top blood pressure reading is 140 mmHg or below

Who may not be able to join:

• People who have AFF on their ECG and are currently taking digoxin
• People who have had a heart event or procedure within the last 3 months that may have changed their heart's pumping function, such as a heart attack, heart surgery, valve surgery, artery-opening procedures, heart rhythm device therapy, or cardiac contractility modulation therapy
• People who are living in a long-term care facility or receiving hospice care
• People whose doctors estimate they have less than 12 months to live due to a condition unrelated to their heart
• People who have received intravenous (IV) medications to support heart pumping or blood pressure within 3 days before screening
• People who have been on mechanical support for heart function or mechanical breathing assistance within 7 days before screening
• People who have received IV water pills, IV blood vessel-relaxing medications, or supplemental oxygen within 12 hours before screening (except for overnight oxygen used for sleep apnea or heart failure)
• People whose kidneys are functioning at a very low level (eGFR below 20 mL/min/1.73m²) or who are on dialysis at the time of screening
• People who have previously received a solid organ transplant
• People currently taking part in another clinical trial of an experimental treatment, or who finished such a trial within the last 30 days
• People who have previously received a drug called omecamtiv mecarbil in a clinical trial
• People who are pregnant, planning to become pregnant during the study, or planning to breastfeed during treatment or within 5 days after finishing treatment
• People whose heart failure is caused by certain specific underlying conditions, such as a protein build-up disease of the heart (such as cardiac amyloidosis) or severe narrowing of a heart valve

Important: Always verify eligibility with the trial site directly before applying.